Cargando…
Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection
Autores principales: | Youssef, Soundos, Lavian, Jonathan, Lee, Eunice Y., Fan, Weijia, Bordone, Lindsey A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the American Academy of Dermatology, Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085348/ https://www.ncbi.nlm.nih.gov/pubmed/35551958 http://dx.doi.org/10.1016/j.jaad.2022.05.005 |
Ejemplares similares
-
Clinical response to oral tofacitinib in pediatric patients with alopecia areata
por: Youssef, Soundos, et al.
Publicado: (2022) -
Alopecia areata after SARS-CoV-2 vaccination
por: Scollan, Margaret E., et al.
Publicado: (2021) -
Validation of Case Identification for Alopecia Areata Using International Classification of Diseases Coding
por: Lavian, Jonathan, et al.
Publicado: (2020) -
A retrospective study of oral tofacitinib therapy for alopecia areata()
por: Lima, Xinaida Taligare Vasconcelos, et al.
Publicado: (2023) -
Oral tofacitinib effectively treating eruptive and hypertrophic cutaneous lichen planus
por: Youssef, Soundos, et al.
Publicado: (2023)